RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis

<table>Forest plot of percentage change in BMD from baseline of denosumab versus placebo at lumbar spine.  Vertical bar outlines the percentage difference in BMD between denosumab and placebo at lumbar spine at 36 months [<a href="/journals/jos/2011/941310/#B30">30</a>].      </table>

Journal of Osteoporosis

fig3

Figure 3

Figure 3: RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis 